You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials
|
|---|---|
| Published in |
Multiple Sclerosis Journal – Experimental, Translational and Clinical, May 2018
|
| DOI | 10.1177/2055217318778610 |
| Pubmed ID | |
| Authors |
Jutta Gärtner, Tanuja Chitnis, Angelo Ghezzi, Daniela Pohl, Wolfgang Brück, Dieter Adrian Häring, Goeril Karlsson, Norman Putzki |
| Abstract |
Disease activity differs in young patients with multiple sclerosis (MS) compared with the overall adult MS population. The objective of this paper is to evaluate the effect of fingolimod 0.5 mg on disease activity in young adults with MS from three randomized, double-blind Phase 3 trials. Annualized relapse rate (ARR), number of new/newly enlarging T2 lesions (neT2), and no evidence of disease activity (NEDA-3) were estimated in the intent-to-treat population at age 20 (youngest) and 30 (young) and compared to the overall population. Models used included a negative binomial regression (ARR/neT2) and a logistic regression (NEDA), with age at baseline as a continuous covariate. ARRs were higher in younger patients (all p < 0.05), and significantly reduced with fingolimod versus placebo or interferon beta-1a (IFN β-1a), with the percentage reduction inversely proportional to age. Fingolimod was significantly associated with a lower number of neT2 lesions versus placebo/IFN in all age groups except versus IFN in the youngest patients. Regardless of age, fingolimod-treated patients were more likely to achieve NEDA-3 versus placebo/IFN β-1a, with strongest benefits in the youngest patients (all p < 0.05). Young adults show higher levels of MS disease activity, and may particularly benefit from fingolimod treatment compared with the overall study population. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Spain | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 63 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 16% |
| Researcher | 6 | 10% |
| Student > Master | 6 | 10% |
| Student > Ph. D. Student | 5 | 8% |
| Student > Doctoral Student | 5 | 8% |
| Other | 13 | 21% |
| Unknown | 18 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 27% |
| Neuroscience | 13 | 21% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Unspecified | 3 | 5% |
| Other | 6 | 10% |
| Unknown | 18 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2018.
All research outputs
#4,120,927
of 25,382,440 outputs
Outputs from Multiple Sclerosis Journal – Experimental, Translational and Clinical
#88
of 373 outputs
Outputs of similar age
#74,872
of 344,607 outputs
Outputs of similar age from Multiple Sclerosis Journal – Experimental, Translational and Clinical
#7
of 14 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 373 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,607 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.